Sobi, which currently has a drug under FDA review as a later line of therapy for gout, is paying $950 million to acquire Arthrosi Therapeutics, a startup with a gout drug candidate in Phase 3 ...
Swedish Orphan Biovitrum AB (Sobi) announced Wednesday morning that it is acquiring CTI BioPharma, a Seattle-based company focused on developing treatments for rare diseases and blood cancers, for ...
- Acquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectory "The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results